These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11758582)

  • 1. Patenting drug products: anticipating Hatch-Waxman issues during the claims drafting process.
    Mahn TG
    Food Drug Law J; 1999; 54(2):245-53. PubMed ID: 11758582
    [No Abstract]   [Full Text] [Related]  

  • 2. The Hatch-Waxman Act during patent prosecution and beyond.
    Mahn TG
    Food Drug Law J; 1999; 54(2):233-6. PubMed ID: 11758578
    [No Abstract]   [Full Text] [Related]  

  • 3. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ
    Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ
    Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
    [No Abstract]   [Full Text] [Related]  

  • 5. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 6. A new history and discussion of 180-day exclusivity.
    Korn DE; Lietzan E; Scott SW
    Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB
    Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
    [No Abstract]   [Full Text] [Related]  

  • 8. The biotechnology industry organization's view on Hatch-Waxman reform.
    Schmickel D
    Food Drug Law J; 1999; 54(2):241-2. PubMed ID: 11758580
    [No Abstract]   [Full Text] [Related]  

  • 9. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 10. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 11. The History and Political Economy of the Hatch-Waxman Amendments.
    Lietzan E
    Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
    [No Abstract]   [Full Text] [Related]  

  • 12. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protecting the balance of Hatch-Waxman: understanding the industry's new dynamics for the 21st century.
    Schroeder RG; Papas P
    Food Drug Law J; 2001; 56(1):19-26. PubMed ID: 11942348
    [No Abstract]   [Full Text] [Related]  

  • 14. Issues in the interpretation of 180-day exclusivity.
    Lietzan E; Korn DE
    Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
    [No Abstract]   [Full Text] [Related]  

  • 15. GATT implementation and generic drug approval.
    Safir PO; Lassman SM
    Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
    [No Abstract]   [Full Text] [Related]  

  • 16. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 17. Judicial developments in the US Hatch-Waxman infringement safe harbor.
    Swirnoff AH; Becker DM
    Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 20. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.